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Brachytherapy: A New Weapon Against Coronary Restenosis
Robert Silver, MD, Resident, Department of Internal Medicine 1999-2002

Since its introduction in the late 1970’s, coronary angioplasty
has become a common procedure for treating coronary atherosclerotic disease. It offers significant improvement in symptoms of coronary artery disease through a less invasive
procedure than coronary artery bypass grafting (CABG). Each
year, over 500,000 percutaneous transluminal coronary
angioplasty (PTCA) procedures are performed in North
America alone. In larger epicardial vessels that are 3 millimeters or greater in diameter, a metal stent can be placed during angioplasty to reduce the incidence of restenosis. In fact,
stents are now deployed in approximately 80 percent of
PTCA procedures. The success rate of PTCA in achieving
significant dilatation of stenotic lesions and relief of symptoms of angina approaches 90 percent. However, restenosis
occurs in approximately 30 to 40 percent of patients within
six months of PTCA alone, and in 20 to 30 percent of
patients who undergo stent placement. Repeat PTCA can be
performed following restenosis, but the risk of further
episodes of restenosis increases as well.
The mechanism behind coronary artery restenosis is believed
to be a combination of factors mitigated by responses to vessel injury caused by PTCA, including remodeling of the
1
damaged artery and thickening of the artery intima .
Stenting does reduce the risk of restenosis by 30 to 50 percent over balloon angioplasty alone, by preventing the constrictive remodeling of the artery. However, stenting actually
results in an increase in neointimal proliferation, a mechanism that leads to in-stent restenosis. Peak incidence of
restenosis occurs within three months after stenting and is
rare after twelve months.
A number of interventions to reduce the incidence of restenosis have been studied over the past twenty years.
Pharmacological agents such as ACE-inhibitors, calcium
channel blockers, lipid-lowering agents, steroids, low-molecular-weight heparin, fish oil, and antioxidants have all been
ineffective in significantly inhibiting restenosis. Once instent restenosis develops, no pharmacological or mechanical
therapy (including repeat PTCA, debulking with Rotablator,
or restenting) can effectively reduce recurrent restenosis.
However, one promising new tool developed over the last
several years against in-stent restenosis is brachytherapy,
the delivery of intracoronary radiotherapy. Cardiologists at

Thomas Jefferson University have been participating in
brachytherapy patient trials since 1997, and FDA approval
of two devices for brachytherapy was granted in November
2000. According to data from the triple-blinded STents
and Radiation Therapy (START) trial (which includes
cardiologists from Thomas Jefferson University), in-stent
restenosis is reduced from 41 to 14 percent with the
™
Novoste Beta-Cath intravascular brachytherapy system
2
vs. balloon angioplasty alone . A number of previously published randomized trials including SCRIPPS, WRIST,
PREVENT and Gamma-One have also demonstrated 2437% reduction in restenosis in patients treated with other
3
systems of brachytherapy over placebo .
The brachytherapy procedure at Thomas Jefferson University
begins with selection of an appropriate candidate. Patients
who require the placement of a new mechanical stent during
PTCA are excluded, as studies have shown a significant incidence of late thrombosis when brachytherapy is performed
on freshly implanted stents. Patients are also excluded if they
are considered high risk for the prolonged administration of
antiplatelet agents required after brachytherapy, or have
received prior radiation therapy. Certain patients with tortuous coronary arteries may also be excluded due to mechanical
difficulties in passing the somewhat bulky radiation catheter
through the vessel.
Immediately after the stenosed artery is successfully treated
by angioplasty, a closed-end radiotherapy catheter is inserted
over a coronary guide wire to the appropriate site. A train of
radioactive seeds of Strontium 90/Yttrium 90 is then administered by a Radiation Oncologist using a handheld hydraulic
device. The radiation is administered for the desired amount
of time (usually 3 to 4 minutes) depending on the diameter
of the lesion, and then withdrawn to an afterloader device.
All of the radiation remains in the catheter during the procedure, protecting both the patient and the physician.
According to Michael P. Savage, MD, Director of the
Cardiac Catheterization Laboratory at Thomas Jefferson
™
University Hospital, the Novoste Beta-Cath system used
at Thomas Jefferson offers several advantages over the other
™
FDA-approved device, the Cordis Checkmate system. The
™
Beta-Cath system uses beta-radiation rather than gammaradiation. Beta-radiation presents a lower tissue penetra-
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tion than gamma-radiation, so medical personnel do not
have to leave the catheterization lab during the administration of radiation. The amount of time that beta-radiation dwells in the vessel is also much more reasonable, from
3 to 4 minutes rather than 15 to 20 minutes with gammaradiation. These factors make the use of brachytherapy a
seamless addition to the PTCA procedure for in-stent
restenosis.
The most significant complication of brachytherapy is the
potential development of coronary thrombosis with the first
month after the procedure. The Gamma-One Trial, published in January 2001, revealed a 5.3 percent incidence of
late thrombosis in a group of patients treated with gammaradiation brachytherapy versus 0.8 percent incidence in
4
placebo group (p value = 0.07) . This resulted in a higher
incidence of myocardial infarction due to thrombosis in the
study group over the placebo group. One possible explanation is that the radiation that prevents neointimal hyperplasia also prevents normal endothelium from growing in the
vessel, leading to thrombosis. For this reason, patients at
Thomas Jefferson University Hospital received clopidogrel
for six months after brachytherapy. Trials studying the effect
of prolonged antiplatelet therapy on late thrombosis after
brachytherapy are ongoing.

tion without exposing the patient to any ionizing radiation. In fact, the Department of Cardiology at Thomas
Jefferson University is likely to begin patient trials of
sonotherapy soon. Another possible breakthrough is the
use of drug-coated stents to inhibit the development of
restenosis. Stents have been coated with antithrombic
agents such as heparin and phosphenylcholine, as well as
immunosuppressive agents such as rapamycin and paclitaxel. Both approaches hope to inhibit the neointimal proliferation that can occur in noncoated stents. However,
until these new technologies come into mainstream practice, brachytherapy is likely to offer the most effective
method of preventing coronary restenosis after stenting.
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At the present time, brachytherapy is limited to preventing
further episodes of in-stent stenosis. If coronary radiation
could be used after balloon angioplasty or initial stenting to
prevent restenosis, brachytherapy would have an even larger
role. Investigators at Thomas Jefferson University partici™
pated in the Beta-Cath System Trial to study brachytherapy in this capacity. However, unpublished results from trial
failed to show a significant decrease in the rate of restenosis
with brachytherapy after PTCA than from PTCA alone.
Randomized, large-scale studies are ongoing to examine an
expanded role for brachytherapy. For now, the lack of conclusive data and the higher incidence of late thrombosis
when treating de novo lesions make brachytherapy unsuitable for the prevention of restenosis.
In the near future, physicians and patients can expect even
more weapons in the growing arsenal against restenosis.
Sonotherapy, in which a therapeutic ultrasound wave is delivered after angioplasty, promises to inhibit intimal prolifera-
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